Patient’s Come First, as Pharma Companies Try to Please with Innovation in Drug Delivery, According to GBI Research
26 Sep 2012 • by Natalie Aster
Drug delivery can utilize various routes, with medication most commonly being administered orally or intravenously. Other routes include topical delivery, through the skin, or transmucosal delivery through the vagina, rectum, eye, nose, cheek, or under the tongue.
According to the new GBI Research report "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance", sophisticated drug delivery systems can cater for patient requirements, or those of the molecule itself. Certain drug delivery systems can promote patient adherence with medication schedules, potentially improving efficacy outcomes and making products more cost effective, thereby providing commercial opportunities for pharmaceutical companies. Drug delivery methods can enable the use of promising molecules which have poor solubility, or require selective delivery to a particular tissue, such as the brain. Drug delivery technologies can enable companies to differentiate their products within crowded therapeutic areas, or improve upon existing drugs. The commercial success of innovative drug delivery technologies is clear, and the driving market competition creates significant positive changes for many patients.
Failure to understand patient needs can ultimately cause the commercial failure of a product, and drug delivery researchers will therefore benefit from contact with patients, identifying their most pressing needs and developing products around these. However, proof will be needed to back up claims that drug delivery methods are not a waste of valuable R&D funding. For instance, the link between convenience and adherence with medication schedules will come under closer scrutiny in the future, as reimbursement companies will demand clinical data to support the superiority of less frequent dosing regimens.
Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
Published: September, 2012
Price: US$ 3.500,00
More information can be found in the report “Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance” by GBI Research.
To order the report or ask for sample pages contact [email protected]